PARP6-dependent vimentin ADP-ribosylation prevents myofibroblast activation in cardiac fibrosis

Abstract

Cardiac fibrosis is a central driver of adverse remodeling during heart failure, yet the post-translational regulation of myofibroblast activation remains poorly defined. Here, we identified PARP6 as a mono-ADP-ribosyltransferase that repressed myofibroblast activation through the ADP-ribosylation of vimentin. PARP6 expression was reduced in failing human hearts and Parp6 haploinsufficiency in mice was sufficient to induce cardiac fibrosis. At the cellular level, PARP6 ADP-ribosylated vimentin thereby limiting actin stress fiber formation. Mechanistically, PARP6 inhibition enhanced RhoA activation and vimentin-RhoA complex formation, thus activating the RhoA-ROCK-LIMK-cofilin pathway. Consistently, Parp6 haploinsufficiency was associated with increased cofilin phosphorylation in mice hearts. In primary cardiac fibroblasts, PARP6 inhibition promoted RhoA-dependent actin stress fiber accumulation and induced myofibrotic protein expression. Together, these findings define a PARP6-vimentin(ADP-ribosylation)-RhoA axis that restrained contractility-driven fibroblast activation, indicating a cardioprotective role of PARP6 with potential therapeutic relevance for fibrotic heart disease.